Grant Life Sciences, Inc. Announces New Stock Symbol and Name Change

Name	Symbol	Market	Type
AGF Global Infrastructure ETF	AMEX:GLIF	AMEX	Exchange Traded Fund

Name

Symbol

Market

Type

AGF Global Infrastructure ETF

AMEX:GLIF

AMEX

Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	25.2679				0	01:00:00

Price Change

% Change

Price

High Price

Low Price

Open Price

Traded

Last Trade

0.00

0.00%

25.2679

01:00:00

Grant Life Sciences, Inc. Announces New Stock Symbol and Name Change

15/11/2004 9:29pm

PR Newswire (US)

AGF Global Infrastructur... (AMEX:GLIF)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more AGF Global Infrastructur... Charts.

Grant Life Sciences, Inc. Announces New Stock Symbol and Name Change SALT LAKE CITY, Nov. 15 /PRNewswire-FirstCall/ -- Grant Life Sciences, Inc., [OTC Bulletin Board: GLIF] announced the Company's common stock symbol has changed from OTCBB: GRTV to OTCBB: GLIF effective at the opening of the market tomorrow, November 16, 2004. This coincides with the Company's name change from Grant Ventures, Inc. to Grant Life Sciences, Inc. Stan Yakatan, CEO and Chairman of Grant Life Sciences, stated, "This ticker and name change was done to better reflect our ongoing business focused on the area of life sciences and diagnostics. Our current lead program is the development of a more efficient test for the diagnosis of cervical cancer. We are very excited about this non-invasive, blood test to screen woman, that could be potentially used as an adjunct to a Pap smear in developed nations and also to target the 1.7 billion women globally who have never received a Pap smear for cultural, religious or economic reasons." About Grant Life Sciences, Inc. Grant Life Sciences, Inc. develops products to improve the efficiency of diagnosing cervical cancer. The Company currently is developing protein-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. This screening test analyzes blood for the presence of certain antibodies that appear only when cervical cancer or certain pre-cancerous conditions are present. Invasive cervical cancer kills approximately 300,000 women annually. Currently, there are more than 120 million cervical screening tests administered annually in the United States and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears and globally 1.7 billion women over the age of 20 do not undergo regular cervical cancer testing. Forward-Looking Safe Harbor Statement: This press release contains forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see our filings with the Securities and Exchange Commission. DATASOURCE: Grant Life Sciences, Inc. CONTACT: Stan Yakatan, Chief Executive Officer of Grant Life Sciences, +1-310-374-0808; or Brian Korb, Senior Associate of The Trout Group, +1-212-477-9007 x23

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

GLIF AGF Global Infrastructure ETF